
CLOV Stock Forecast & Price Target
CLOV Analyst Ratings
Bulls say
Clover Health Investments is well-positioned for continued financial performance. With strong retention in geographies with CA adoption, the company's 95%+ retention for 2026 bodes well for continued medical cost performance. The company's CA-powered physicians have seen better health outcomes and lower costs, leading to a 8% MCR differential compared to physicians who do not use CA. Additionally, the company's growth in markets with high CA adoption and strong member retention means there will be a strong base of members being seen by physicians powered by CA, which is expected to drive profitability in 2027.
Bears say
Clover Health Investments is facing potential headwinds due to regulatory changes and increased competition in the Medicare Advantage market. Its unique care model, Clover Assist, may experience volatility in managing medical expense trends. The company also faces liquidity risks, which could result in dilutive equity financing. While its recent membership growth and profitability expectations for 2026 are positive, concerns remain about the sustainability of this growth and overall profitability.
This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.
CLOV Analyst Forecast & Price Prediction
Start investing in CLOV
Order type
Buy in
Order amount
Est. shares
0 shares